Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now locked in another big biotech deal.

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

Swiss pharmaceutical firm Novartis said on Tuesday that it has agreed to buy privately held, clinical-stage US biotech Anthos ...

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...

Anthos is currently conducting a phase 3 clinical study in patients with atrial fibrillation with high risk for stroke or systemic embolism (LILAC-TIMI 76) as well as two phase 3 studies in patients ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody ...

Astronomers are baffled by EP240408a, a rare cosmic explosion that defies explanation, sparking theories of a black hole and ...

The Indian stock market continued its downward spiral for the fifth consecutive session, with the Sensex plunging 1,018 ...

ISRO confirms SpaDeX docking completed without issues Orbit raising stalled due to oxidiser valve malfunction Future experiments planned to enhance docking tech ...

Basel: Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, ...